After 50 years of research and the testing of over 1,000 drugs, there is new hope for preserving brain cells for a time after stroke. Treating acute ischemic stroke patients with an experimental neuroprotective drug, combined with a surgical procedure to remove the clot improves outcomes as shown by clinical trial results published today in The Lancet.
In a comparison of 0.25mg/kg and 0.40mg/kg doses of the newer and more convenient clot-busting medication tenecteplase, there was no advantage in increasing the dose above 0.25mg/kg in stroke patients who planned to have mechanical clot retrieval. In addition, administering tenecteplase may decrease the need for mechanical clot removal.
A new, non-invasive wearable magnetic device that stimulates the brain to rewire itself is safe and could improve recovery for stroke survivors. The technology could be a step to help improve motor function after stroke.
Placing stents in cholesterol-clogged brain arteries may be an option to reduce the risk of a repeat stroke. However, it is too soon to know if stenting in the brain arteries improves long-term patient outcomes.
Stroke patients were more likely to get clot-busting treatment and received it faster if treatment started in a mobile stroke unit, an ambulance specially equipped to provide treatment. Those treated in a mobile stroke unit had less post-stroke disability, a German study found.
Adding a combination of three natural extracts to standard pharmacological treatments could help to fight hypertension, improving cardiovascular function especially in those patients whose blood pressure remains not well controlled. These are the conclusions of a study conducted by the Vascular Pathophysiology Laboratory of I.R.C.C.S. Neuromed in Pozzilli, in collaboration with the Medical University of Salerno, Federico II University in Naples, I.R.C.C.S. Multimedica in Milan, and Sapienza University of Rome.
Multi-country intervention trial to improve hypertension management, led by Duke-NUS Medical School in Singapore, in partnership with the International Centre for Diarrhoeal Diseases Research, Bangladesh (ICDDR,B), Aga Khan University in Pakistan, the University of Kelaniya in Sri Lanka and the Singapore Clinical Research Institute (SCRI), leads to "clinically meaningful" reductions in blood pressure and better blood pressure control in patients receiving the multi-component intervention. Researchers call for national scale-up of the intervention.
The financial burden on health systems would drastically increase if new European expert guidelines for cholesterol-lowering treatment were implemented, according to a new simulation study by researchers at Karolinska Institutet in Sweden, published in the European Heart Journal. The findings highlight an urgent need for cost-effectiveness analysis given the current cost of the proposed treatment for very high-risk patients, the researchers say.
New University of Kentucky research shows that the immune system may target other remote areas of the brain to improve recovery after a stroke.
New guidelines recommend aspirin use in primary prevention for people ages 40 to 70 years old who are at higher risk of a first cardiovascular event, but not for those over 70. Yet, people over 70 are at higher risks of cardiovascular events than those under 70. As a result, health care providers are understandably confused about whether or not to prescribe aspirin for primary prevention of heart attacks or strokes, and if so, to whom.